Related Experiment Video
Updated: Sep 15, 2025

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
Published on: February 25, 2022
ECM1 expression in chronic liver disease: Regulation by EGF/STAT1 and IFNγ/NRF2 signalling
Yujia Li1, Chenjun Huang1,2, Weiguo Fan3
1Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Epidermal Growth Factor (EGF)/Signal Transducer and Activator of Transcription 1 (STAT1) signaling promotes extracellular matrix protein 1 (ECM1) expression, preventing liver fibrosis. Interferon gamma (IFNγ)/Nuclear Factor erythroid 2-related Factor 2 (NRF2) signaling inhibits ECM1, accelerating chronic liver disease (CLD).
Area of Science:
- Hepatology and Molecular Biology
- Extracellular Matrix and Fibrosis Research
Background:
- Extracellular matrix protein 1 (ECM1) is crucial for liver homeostasis, maintaining latent transforming growth factor-beta quiescence.
- ECM1 downregulation upon hepatocyte damage accelerates fibrosis and chronic liver disease (CLD) progression.
Purpose of the Study:
- To elucidate the regulatory mechanisms of ECM1 expression in hepatocytes under pathophysiological conditions.
- To investigate the role of ECM1 in the context of liver inflammation and fibrosis.
Main Methods:
- Promoter analysis to identify ECM1 transcriptional regulators.
- Single-cell and bulk RNA sequencing to assess ECM1-related gene expression.
- Functional assays using cell lines, primary hepatocytes, and clinical/preclinical liver tissues.
Main Results:
- Epidermal Growth Factor (EGF)/EGF Receptor (EGFR) signaling, via STAT1 phosphorylation at S727, enhances ECM1 transcription in healthy hepatocytes.
- Interferon gamma (IFNγ) disrupts this pathway by downregulating EGFR and promoting STAT1 phosphorylation at Y701, impairing ECM1 promoter binding.
- IFNγ also induces Nuclear Factor erythroid 2-related Factor 2 (NRF2) nuclear translocation, repressing ECM1 expression; AAV8-ECM1 therapy attenuated fibrosis in mice, and ECM1 levels correlated with EGFR and IFNγ/NRF2 in CLD patients.
Conclusions:
- EGF/STAT1 signaling promotes ECM1 expression, while IFNγ/NRF2 signaling inhibits it in hepatocytes during health and disease, respectively.
- ECM1 demonstrates potential as an antifibrotic agent, particularly for CLD driven by inflammation or oxidative stress.
- Understanding these regulatory pathways offers potential therapeutic targets for CLD patients.
More Related Videos
Related Concept Videos
Cell Specific Gene Expression
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Regulation of Angiogenesis and Blood Supply
Master Transcription Regulators

